Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them. Send request.
Active ingredient:
EZETIMIBE; SIMVASTATIN
Available from:
MERCK SHARP & DOHME ISRAEL LTD
ATC code:
C10AA01
Pharmaceutical form:
TABLETS
Composition:
SIMVASTATIN 20 MG; EZETIMIBE 10 MG
Administration route:
PER OS
Prescription type:
Required
Manufactured by:
MERCK SHARP & DOHME B.V., THE NETHERLANDS
Therapeutic group:
SIMVASTATIN
Therapeutic area:
SIMVASTATIN
Therapeutic indications:
Hypercholesterolemia: Inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. Inegy contains ezetimibe and simvastatin. Simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. Studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. Homozygous familial hypercholesterolemia (HoFH): Inegy is indicated as adjunctive therapy to diet for use in patients with HoFH.Patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [LDL] apheresis).
